APPROVED FOR THE TREATMENT OF IPF, SSc-ILD AND PF-ILD
FACE PULMONARY FIBROSIS
and modify disease progression by slowing lung function decline1-6
OFEV® (nintedanib) is approved for the treatment of progressive fibrosing interstitial lung disease (PF-ILD).
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
 

About Pulmonary Fibrosis

 
 

References:

1. MY: OFEV® Malaysia Prescribing Information, January 2020.
2. Distler O, Highland KB, Gahlemann M, et al; the SENSCIS Trial Investigators. Nintedanib for systemic sclerosis-associated lung disease. N Engl J Med. 2019;380(26):2518-2528. doi:10.1056/NEJMoa1903076.
3. Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017;389(10082):1941-1952. doi:10.1016/ S0140-6736(17)30866-8.
4. Richeldi L, du Bois RM, Raghu G, et al; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-2082. doi:10.1056/NEJMoa1402584.
5. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079-1087. doi:10.1056/NEJMoa1103690.
6. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718-1727.

MPR-PH-100057
Production date: May 2019